Semaglutide is a GLP-1 receptor agonist sold as Ozempic/Rybelsus for diabetes and Wegovy for weight loss, mimicking GLP-1 to curb appetite and blood sugar.
NATCO Pharma launched generic semaglutide in India on March 20, 2026, the day key patents expired, with vials from Rs 1,290 a month. Rival prices were not in the March 2026 launch report, so that figure was a benchmark until a competitor tested it.
Reality
Exponential View says GLP-1 sales reached $76 billion in 2025, ahead of its own $63 billion estimate for generative AI. The $13 billion lead rests on that estimate, and the retention studies the piece cites show heavy attrition.
Reality
Novo Nordisk and Eli Lilly say patients on their GLP-1 drugs measured two to three years younger on molecular aging clocks than those on placebo. The size of that drop swings with which clock is used and which organ it reads.
Reality
Retatrutide's 12 mg dose cut body weight 25% over 80 weeks, versus 3.9% on placebo, in a 2,339-adult phase 3 trial in NEJM. Its near-30% two-year figure comes from 532 completers, and because placebo was the only comparator, the trial cannot rank the drug against Ozempic.
Reality
Eli Lilly's retatrutide cut body weight by more than 20% on average at its top dose in an 80-week phase 3 trial of 1,152 people with type 2 diabetes. Lilly calls that a first for the field, and it gives the four- and five-receptor drugs now in development a figure to beat in patients with diabetes.
Reality
One personal injury firm has filed more than 90 New Jersey suits claiming Novo Nordisk's Ozempic and Wegovy caused sudden vision loss. Denmark has awarded about $55,600 a patient for the same injury, the only price on record, while studies of whether the drugs cause it still disagree.
Reality
Veterans with type 2 diabetes who came off semaglutide or tirzepatide lost most of the cardiovascular benefit within two years, and the benefit only appeared in patients who had stayed on the drug past 18 months.
Reality
The 2035 diversification target Novo gave investors in London is a single risk-adjusted total that includes assets already in the pipeline, and the launch list it published for 2027 through 2030 is almost all GLP-1 and amylin.
Reality
A University of Pennsylvania group read five years of GLP-1 discussion from nearly 70,000 Reddit users and came out with two symptom families worth a real study, plus a nausea signal that shows the method finds what is already known.
Reality
Semaglutide's approval starts above age 12 and tirzepatide's obesity approval at 18, but a published study and one Dallas hospital's own count both show children under 12 already taking these drugs, mostly for obesity and type 2 diabetes.
Reality
An NIH-funded UC Berkeley team dosed old, healthy female mice, then fed a second group 24% fewer calories to match what the drug's appetite suppression achieved. The drug still did more on memory and blood sugar.
Reality
A Berkeley group ran the drug against a matched 24 percent food cut and found it equalled dieting on strength and coordination while beating it on memory and glucose. The lifespan race between the two is still running.
Perspective Coverage
3 publishersReality
All three arms shed about a tenth of their body weight and improved muscle insulin sensitivity, so the separation showed up in the liver, where the keto arm cut fat and triglyceride production. Delivered meals bought the adherence that makes that readable.
Reality
A Yale mouse study in PNAS reports that semaglutide activates AgRP neurons, and that animals lacking those neurons cannot sustain fat loss on the drug.
Reality
A 2026 JAMA Surgery analysis shows surgical obesity care losing a third of its volume in two years. The spend has not vanished; it has moved to the pharmacy benefit, where coverage decides who gets treated.
Reality
Enveda's ENV-308, a mimic of the exercise hormone Lac-Phe, was safe and well tolerated in its first human trial. The muscle-sparing weight-maintenance pitch is still a hypothesis.
Reality
A small semaglutide trial reported endocrine gains, not just weight loss, in a condition affecting one in eight women. Fortune reports insurers are already putting up barriers.
Reality
Measured US adult obesity sat at 40.3 percent across 2013 to 2023 while severe obesity rose from 7.7 to 9.7 percent. The programs did not bend the line, and benefits committees now own the question.
Reality